<DOC>
	<DOC>NCT02750800</DOC>
	<brief_summary>This study aims at evaluate the effect of adalimumab with patient support program (PSP) on clinical, health economic, patient reported outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease and ulcerative colitis in the routine clinical setting in Hungary.</brief_summary>
	<brief_title>Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Diagnosis of RA, AS, PsA, Ps, CD or UC by treating physician. RA, AS, PsA, Ps, UC or CD patients whom adalimumab treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional/reimbursement guidelines. Subjects assigned to adalimumab treatment not more than 1 month prior to inclusion. Patient to whom participation in AbbVie CARE 2.0 Patient Support Program (PSP) program was offered and patient decided to join and has started the PSP. Patients willing to be involved in the study and to sign patient informed consent form (ICF) and subject information form (SIF) in order to allow use and disclosure of his/her personal health information. Patients who cannot be treated with adalimumab according to the local adalimumab SmPC and local professional and reimbursement guidelines. Patients treated with &gt; 1 prior biologic DMARD for RA, AS, PsA, Ps, UC or CD. Prior treatment with adalimumab for more than 1 month. Patients currently participating in other clinical research. Patients who are unwilling or unable to complete the quality of life and other patient reported questionnaires. Patients who choose not to participate in ABBVIE Care 2.0.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Patient related outcomes</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Patient support program</keyword>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Observational study</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Crohn's disease</keyword>
</DOC>